Parkinson's Foundation Appoints Utah Tech CEO Cory Pinegar as President and Board Member of Newly Formed Rocky Mountain Chapter Board of Advisors
08 juin 2022 12h15 HE
|
The Parkinson's Foundation
SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- The Parkinson's Foundation has named visionary entrepreneur Cory Pinegar as President of the Rocky Mountain Chapter Board of Advisors and Board...
Zhittya Genesis Medicine Completes its First-In-Human Study with a Novel Intranasal Treatment for Parkinson’s Disease
08 juin 2022 11h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 08, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it has completed its first-in-human research study for the treatment of...
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
31 mai 2022 08h00 HE
|
Denali Therapeutics Inc.
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640...
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
27 mai 2022 11h30 HE
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
12 avr. 2022 13h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression
11 avr. 2022 13h41 HE
|
Clinical Ink
Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today—World Parkinson’s Day—announces research that strengthens its standing as a critical...
A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
17 mars 2022 09h00 HE
|
JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...
Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease
27 janv. 2022 09h00 HE
|
Enterin Inc.
PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
26 janv. 2022 02h55 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease
25 janv. 2022 09h00 HE
|
Enterin Inc.
PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...